Journal home
Advance online publication
Current issue
Archive
Press releases
Free Association (blog)
Supplements
Focuses
Guide to authors
Online submissionOnline submission
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
Reprints and permissions
About this site
For librarians
 
NPG Resources
Nature
Nature Biotechnology
Nature Cell Biology
Nature Medicine
Nature Methods
Nature Reviews Cancer
Nature Reviews Genetics
Nature Reviews Molecular Cell Biology
news@nature.com
Nature Conferences
Nature Reports Stem Cells
RNAi Gateway
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Letter
Nature Genetics  26, 114 - 117 (2000)
doi:10.1038/79089

Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis

Eva González-Suárez1, Enrique Samper1, Juana M. Flores2 & María A. Blasco1

1  Department of Immunology and Oncology, National Centre of Biotechnology, Madrid, Spain.

2  Department of Animal Pathology II, Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid, Spain.

Correspondence should be addressed to María A. Blasco mblasco@cnb.uam.es
Inhibition of telomerase is proposed to limit the growth of cancer cells by triggering telomere shortening and cell death1, 2, 3, 4, 5, 6, 7, 8, 9. Telomere maintenance by telomerase is sufficient, in some cell types, to allow immortal growth1, 2, 3, 4, 5. Telomerase has been shown to cooperate with oncogenes in transforming cultured primary human cells into neoplastic cells, suggesting that telomerase activation contributes to malignant transformation6. Moreover, telomerase inhibition in human tumour cell lines using dominant-negative versions of TERT leads to telomere shortening and cell death7, 8. These findings have led to the proposition that telomerase inhibition may result in cessation of tumour growth9. The absence of telomerase from most normal cells supports the potential efficacy of anti-telomerase drugs for tumour therapy, as its inhibition is unlikely to have toxic effects. Mice deficient for Terc RNA (encoding telomerase) lack telomerase activity, and constitute a model for evaluating the role of telomerase and telomeres in tumourigenesis10. Late-generation Terc -/- mice show defects in proliferative tissues10, 11, 12, 13, 14, 15 and a moderate increase in the incidence of spontaneous tumours in highly proliferative cell types (lymphomas, teratocarcinomas12). The appearance of these tumours is thought to be a consequence of chromosomal instability in these mice10, 12, 16, 17. These observations have challenged the expected effectiveness of anti-telomerase−based cancer therapies18. Different cell types may nonetheless vary in their sensitivity to the chromosomal instability produced by telomere loss or to the activation of telomere-rescue mechanisms. Here we show that late-generation Terc -/- mice, which have short telomeres and are telomerase-deficient10, are resistant to tumour development in multi-stage skin carcinogenesis. Our results predict that an anti-telomerase−based tumour therapy may be effective in epithelial tumours.


 Top
Abstract
Previous | Next
Table of contents
Full textFull text
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

Open Innovation Challenges

naturejobs

Figures & Tables
Export citation
natureproducts

Search buyers guide:

 
ADVERTISEMENT
 
Nature Genetics
ISSN: 1061-4036
EISSN: 1546-1718
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | For authors | Online submission | Permissions | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | naturereprints | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©2000 Nature Publishing Group | Privacy policy